Pfizer is asked to suspend sales of painkillerBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7496.862-a (Published 14 April 2005) Cite this as: BMJ 2005;330:862
- Jeanne Lenzer
- New York
In a move that took experts by surprise, regulatory agencies in the United States and Europe have asked the drug maker Pfizer to suspend sales of its cyclooxygenase-2 (COX 2) inhibitor valdecoxib (Bextra).
The US Food and Drug Administration's move comes less than two months after an advisory panel recommended to the FDA that the drug remain on the market (BMJ 2005;330: 440, 26 Feb).
Pfizer said it …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial